S Bank Fund Management Ltd Has $4.20 Million Stock Holdings in Illumina, Inc. $ILMN

S Bank Fund Management Ltd raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1,973.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,000 shares of the life sciences company’s stock after purchasing an additional 30,457 shares during the quarter. S Bank Fund Management Ltd’s holdings in Illumina were worth $4,197,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Empowered Funds LLC boosted its stake in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Illumina during the second quarter worth $621,000. CW Advisors LLC bought a new position in shares of Illumina during the second quarter valued at $275,000. Marshall Wace LLP boosted its stake in shares of Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC boosted its stake in shares of Illumina by 30.9% in the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent analyst reports. Canaccord Genuity Group dropped their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research report on Friday. Stifel Nicolaus boosted their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Citigroup upped their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday. UBS Group reaffirmed a “neutral” rating and set a $135.00 price objective on shares of Illumina in a report on Friday, February 6th. Finally, Piper Sandler reduced their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $131.06.

Insider Buying and Selling at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Down 0.2%

Shares of NASDAQ:ILMN opened at $139.07 on Wednesday. Illumina, Inc. has a 12 month low of $73.86 and a 12 month high of $155.53. The company’s 50-day moving average price is $126.11 and its two-hundred day moving average price is $127.23. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm has a market cap of $21.13 billion, a P/E ratio of 25.29, a P/E/G ratio of 2.31 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm posted $0.97 earnings per share. The company’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts forecast that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.